Full View

Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 …

GHR Smith, WK Henry, D Podzamczer… - Open Forum …, 2021 - academic.oup.com
Abstract Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2)
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …
被引用次数：33 相关文章

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the …

GHR Smith, WK Henry, D Podzamczer… - Open Forum …, 2021 - search.ebscohost.com
Abstract Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2)
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the …

GHR Smith, WK Henry, D Podzamczer… - Open Forum Infectious …, 2021 - go.gale.com
Background. In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase
2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks (Q8W) or …

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the …

GHR Smith, WK Henry, D Podzamczer… - Open Forum …, 2021 - europepmc.org
Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b
study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks (Q8W) or …
[HTML] nih.gov

[HTML][HTML] Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results …

GHR Smith, WK Henry, D Podzamczer… - Open Forum …, 2021 - ncbi.nlm.nih.gov
Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b
study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks (Q8W) or …

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults with Human Immunodeficiency Virus Type 1 Infection: 5-Year Results from the …

GHR Smith, WK Henry… - Open Forum …, 2021 - vivantes.elsevierpure.com
Background: In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase
2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks (Q8W) or …

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the …

GHR Smith, WK Henry… - Open forum …, 2021 - pubmed.ncbi.nlm.nih.gov
Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b
study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks (Q8W) or …
[PDF] oup.com

[PDF][PDF] Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From …

GHR Smith, WK Henry, D Podzamczer… - Open Forum …, 2021 - academic.oup.com
Abstract Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2)
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults with Human Immunodeficiency Virus Type 1 Infection: 5-Year Results from the …

GHR Smith, WK Henry… - Open Forum …, 2021 - vivantes.elsevierpure.com
Background: In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase
2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks (Q8W) or …